Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Optimizing the efficacy of T-cell based immunotherapies

Nora Zieger • 10 Dec 2021
ASH 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib Flotetuzumab

Sub-optimal response rates remain an issue in patients with acute lymphocytic leukemia (ALL) treated with blinatumomab, a bispecific T-cell engager (BiTE). Nora Zieger, University Hospital, LMU Munich, Munich, Germany, highlights the importance of improving efficacy of T-cell based immunotherapies. Addition of dasatinib, a Src kinase inhibitor, with blinatumomab is found to improve response rates by potentially preventing T-cell exhaustion. She additionally discusses how treatment-free intervals improved the toxicity profile of flotetuzumab in patients with ALL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Nora Zieger

3:21
Treatment-free intervals decrease T-cell exhaustion
Nora Zieger • 10 Dec 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals